Home

Applications to the FDA for orphan drug status for Marshall Protocol medications

Autoimmunity Research Foundation has submitted multiple applications to the Office of Orphan Products Development, a division of the FDA. The goal of submitting these applications would be to make it easier for doctors to prescribe and harder for insurance companies to deny coverage of MP medications.

Minocycline

Clindamycin

<html> <!–

Olmesartan

–!</html>

home/publications/applications_orphan_status.txt · Last modified: 07.04.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.